Patrick Kaltenbach
President & Chief Executive Officer at Mettler-Toledo International
Thanks, Shawn.
Let me start with some comments on our operating businesses, starting with Lab. As Shawn mentioned earlier, excluding the Q4 shipping delay benefits this quarter, local currency sales in our Laboratory business declined approximately 6% compared to last year. This was better than we anticipated, but we saw cautious spending patterns from our pharma and biopharma customers, especially in China. We have a very strong product portfolio and pipeline of new innovations that directly address our customer needs for solutions that enhance their productivity and ensure regulatory compliance. Combined with the enhancements we have made on our Spinnaker sales and marketing program. Our go-to-market approach is a significant competitive differentiator during this period of reduced end-market demand.
Our industrial sales for the quarter were also better than we had expected and declined about 3%, excluding the benefit of shipping delays. Our sales of core industrial products have performed better than we would have expected in a soft economic environment, benefiting from our upgraded portfolio of products that enable automation and digitalization in our customers' production and logistics facilities. We also continue to be optimistic about growth opportunities related to onshoring and near-shoring as customers aim to increase resiliency in their supply chains. Our product inspection business also had better-than-expected performance in a soft market environment with benefits from recent product introductions and strong service growth. Lastly, food retail sales declined in line with our expectations against significant project-driven sales growth in the first quarter of last year.
Now let me make some additional comments by geography. Starting in the Americas. Our sales declined slightly in the quarter, excluding the benefit from recovering of our shipping delays. We benefited from strong project-related growth in industrial, which was offset by a decline in lab and retail. As expected, our customers have been somewhat cautious starting the year, especially in pharma and biopharma, which we expect to improve as we face easier comparisons in the second half of the year. Retail also faced very difficult comparisons related to very strong growth in the prior year. Sales in Europe, excluding the estimated benefit from recovering our European logistics hub delays, declined about 5% and were largely in line with our expectations across each of our businesses.
We continue to see soft economic indicators across most of Europe and acknowledge the potential risk to the European economy and energy prices from the conflict in the Middle East. However, we had a very strong team and go-to-market approach that positions us very well to capture growth opportunities. Lastly, Asia/Rest of the World results were also slightly better than expected, although demand in China remains very weak relative to very strong growth over the past few years. We continue to target pockets of growth opportunities, including semiconductor and new energy industries, and our approach to the market has remained a significant competitive advantage against the competition. Those are all my comments on the businesses for the quarter, and I'd now like to share with you why we are so optimistic on the long-term growth opportunity for our company.
First, I have been in the life science and analytical tools industry for a long time and believe the exciting advancements our customers are bringing to the market will continue to support healthy market growth in our industry over the long term. We also see many new opportunities in fast-growing segments such as sustainable materials, semiconductors, and alternative energy. Our customers also continue to look to us to help them achieve their goals, including improving productivity and quality, while supporting their efforts in automation and digitalization. Our very broad and diverse portfolio of solutions is an important differentiator and we lead the industry with new innovations for our target markets. Innovation is at the heart of our culture and is essential to our continued success.
We are constantly coming out to market with new products and have accelerated our rate of innovation over the past few years. New products help stimulate replacement cycles, support market share gains, and enhance our value proposition that support our pricing. We are uniquely positioned to serve customers throughout the value chain from R&D through production and logistics. This also creates a tremendous opportunity for us to add automation and digitalization features to our products and drive productivity and provide insights throughout the value chain. Over the past three years, we have invested over $0.5 billion in research and development into three key areas.
First, technology advancements to support new products and features that increase the value of our products. Second, application and software development to complement our products. And third, design enhancements to simplify manufacturing and serviceability of our products. The significant investments we are making have been an important contributor to expanding our innovation leadership and market share gains. I'd like to share a few examples of innovations we have recently brought to market and why we are so excited about our future.
I'll start with our biggest launch of the year, our entirely new and redesigned portfolio of standard and advanced level laboratory balances, which you may have seen featured in our annual report. We are the global market leader in laboratory weighing, but also have ample room to gain further market share that includes expanding our access to growth segments. Our new range of balances address this opportunity with the best products for entry-level applications all the way up to advanced weighing requirements. They feature increased robustness, seamless data management, a harmonized user interface, and up to 30% better measurement and performance. Our design approach also improves sustainability, and using improved packaging and reducing their power consumption.
Weighing is a critical step in the sample preparation process and our LabX software connects our higher-end balances to our broad portfolio of analytical instruments to help automate workflows and ensure secure and compliant data capture. This is a very important competitive advantage considering we provide about 40% of the instruments that are found in a typical quality control lab and we recently introduced several new analytical instruments with new automation and digitalization features. For example, we are the global number two player in titration and last month, we launched two completely new Karl Fischer titrator models.
Our new EVA titrators are ideal for efficiently determining the water content of challenging samples and our new control algorithm speeds up reaction rates and allows for faster analysis and cycle times. It also has an automated solvent exchange system that ensures safety by minimizing exposure to potentially hazardous chemicals. Importantly, our new titrators have full compatibility with our LabX software to enable automated seamless workflows with secure data management, all while complying with data integrity regulations. Hot segments have been an important driver of growth for analytical instruments and water determination through titration is an important part of lithium battery production.
Our Voice of Customer program, Jetstream uncovered a specific customer need in the market to be able to analyze multiple samples with only one titration instrument. To address this, our team developed a new automated sample prep solution, the In-Motion Karl Fischer Six that is used with our titrator. With our In-Motion Six, customers can process up to six samples fully automatically and unattended with only one titrator, addressing our customers' need for a cost-effective solution on a very small footprint. Automation has also been an important differentiator for our thermal analysis customers in fast-growing markets such as development of new materials, and we recently introduced a new thermal analysis instrument called the DSC 5+ with a fully automated sample changer. This instrument also increases the efficiency of the entire workflow from sample handling to result assessment, generating reproducible results with less resources.
Our Artificial Intelligence Wizard software automatically detects and evaluates many types of thermal effects, saving valuable time and providing consistent and reliable measurement results regardless of the user's level of experience. Our software also has different neural networks that are trained on dedicated data, so customers can download the most appropriate package for their experiment. Our core industrial business has been very successful in integrating advanced automation and connectivity features into its products and has focused its new product development on terminals and digital load cells that provide seamless integration into factory automation systems. A great example of this is our Industry 360 terminal, which is an ultra-fast weight indicator for automated filling, dosing, and tank weighing applications across a variety of industries from biopharma to food manufacturing.
The terminal connects our scales and weighing sensors and seamlessly integrates our pre-programmed ready-to-use weighing applications into a customer's programmable logic controllers for process control automation. It also seamlessly feeds data to customer IT systems and because of our unique ability to combine IT and operations technology communication on a single network, it saves customers integration and programming cost and time and eliminates the need for an additional gateway to the server or cloud. This product line has been very successful and new derivatives like our Industry 700 and Industry 400 have been very recently launched to further expand our portfolio.
We have also expanded our capabilities in pharma manufacturing IT systems, helping customers by having a simplified and standardized integration of our weighing solutions. These advanced terminals also connect to our new PHD low-profile hygienic floor scale family that offers unmatched hygiene and safety features. Our new scales are very well suited for industries like pharma where cleanliness is paramount. These scales offer a unique fully sealed design that reduces contamination risks and simplify cleaning procedures and also has a state-of-the-art digital load cell.
We have had great success with the 2023 launch of this product and we believe this and other new core industrial products have been very important contributor to the relative resilience of this business over the past year. We have also recently launched several new products across our product inspection business over the past year that are highly differentiated and bring considerable value to the customers. We expect these innovations, including our new series of X-ray inspection technology to help drive market-share gains, especially in the mid-market segment. We have an excellent pipeline of innovations of product inspection that will further build on our market leadership.
Lastly, we are also pleased with our success of food retail business that they have seen with new product introductions like our FreshBase scales, which was an important contributor to the market share gains and strong sales growth last year. Additionally, our new FreshBase Plus AI scale with advanced image recognition technology is an exciting innovation we are looking forward to bringing to additional markets outside of China. So that is a brief overview of a few new products we have launched over the past year. And we have many more to come this year as we have accelerated certain innovation investments to capture growth opportunities. These investments continue to provide a portfolio that is stronger than ever and continues to increase our value proposition and most importantly help our customers gain new insights, increase their productivity, and ensure regulatory compliance throughout their value chain. That is the conclusion of our prepared remarks.
Operator, I'd like to open the line now to questions.